Administration of stem cells for rejuvenation and geriatric support.
Andrey S. Bryukhovetskiy
The methodological basis for the clinical administration of the hematopoietic stem cells (HSCs) and hematopoietic precursor cells (HPCs) for ageing is provided by the fundamental scientific concept about steadily reducing number of the HSCs, HPCs and mesenchymal stromal stem cells (MSSCs) with the time. Normally, the peripheral blood of a 20-years old person the number of the HSCs and HPCs is about 0.01% of the general number of the cells of the peripheral blood, while administration of the granulocyte colony stimulating growth factor (G-CSF) increases their percentage to 1.5 or even 2%. The number of the MSSCs iт the peripheral blood is close to that of HSCs. But by the age of 60 their number reduced tenfold or even more.
This leads to reduced regenerative potential of the cells, though this number is sufficient for blood formation till the age of 120 and even more. This phenomenon can be explained by the fact that the hematopoietic stem cells have the largest life cycle among other cell cycles of the human body which totals 360 days. According to the mathematical theory of the systems’ control, the slowest process controls the system. This is the reason why the HSCs and HPCs are the main regulators in the intratissular intercellular relations and the central regulatory systems of the intercellular interactions in the complex hierarchy of the blood cells.
Age-induced deficit of the HPCs and HSCs along with the MSSCs leads to the immune disorders represented as secondary immunodeficiencies, long-term disorders of the hemopoiesis system and coagulation, suppressed functioning of endocrine organs and system and hypofunction of the lymphatic system. Administration of the HSCs and HPCs for rejuvenation accelerates regenerative and reparative processes, normalizes endocrine status, restores the disorders of the secondary immunodeficiencies in chronic infectious diseases.
Administration of the immunocompatible allogeneic HSCs and HPCs improves skin elasticity, modulates metabolic disorders in the tissues, activates sexual function, including higher libido and erection. Regular administrations of autologous HSCs and HPCs before age of 60 and immunocompatible donor HPCS and HSCs after 65 show statistically valid restoration of immunity, hemopoiesis, improve endocrine status and coagulation, activate muscle tone and balance emotional-volitional sphere.
Such clinical effects have been registered in 75% of 65 patients who received the course of rejuvenation according to the proposed therapy. In 10.8% the clinical observations have been inapparent and in other cases no clinical effect has been observed. However, the paraclinical indicants, such as hormonal status, immune status, interferon status and other, demonstrated improved somatic condition after the regular infusions of the hematopoietic cells.